Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
54 studies found for:    Chest MRI | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
21 Recruiting Study and Treatment of Inflammatory Muscle Diseases
Conditions: Autoimmune Disease;   Dermatomyositis;   Inclusion Body Myositis;   Myositis;   Polymyositis
Intervention:
22 Recruiting Detection and Characterization of Host Defense Defects
Conditions: Immunologic Deficiency Syndrome;   Infection
Intervention:
23 Recruiting Cardiovascular Disease Screening
Conditions: Congenital Heart Disease;   Atherosclerosis;   Myocardial Ischemia;   Myocardial Infarction;   Acquired Heart Disease
Intervention:
24 Recruiting Metastasectomy Study in Renal Cell Carcinoma (RCC)
Condition: Kidney Cancer
Intervention: Other: Evaluation
25 Recruiting Reduced Immunogenicity Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Condition: Mesothelioma
Intervention: Drug: LMB-100
26 Recruiting Screening Patients for NCI Protocol Eligibility
Conditions: Breast Cancer;   Prostate Cancer;   Lung Cancer;   Sarcoma;   Melanoma
Intervention:
27 Recruiting Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
Condition: Prostate Cancer
Intervention:
28 Recruiting Detection and Characterization of Infections and Infection Susceptibility
Conditions: Immune Disorders;   Chronic Granulomatous Disease;   Genetic Immunological Deficiencies;   Hyperimmunoglobulin-E Recurrent Infection Syndrome;   Recurrent Infections;   Unknown Immune Deficiency;   GATA2 Deficiency (MonoMAC);   Nontuberculous Mycobacterial Infections;   Hyper IgE (Job s) Syndrome;   Leukocyte Adhesion Deficiency;   Susceptibility to Disseminated Infections;   Primary Immune Deficiency Disease (PIDD)
Intervention:
29 Recruiting A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldeslaukin;   Drug: Pembrolizumab;   Biological: young TIL
30 Recruiting Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
Conditions: Renal Cancer;   Chromophobe Renal Cell Carcinoma;   Birt-Hogg-Dube Syndrome
Intervention: Drug: Everolimus
31 Not yet recruiting Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Conditions: Glioblastoma;   Glioblastoma Multiforme;   Gliosarcoma;   Brain Neoplasms;   Central Nervous System Neoplasms
Interventions: Drug: topotecan;   Drug: pazopanib
32 Recruiting Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Condition: Cardiac Disease
Intervention:
33 Recruiting Natural History of Stroke: Cause and Development
Conditions: Nervous System Disease;   Transient Ischemic Attack;   Neurologic Disorders;   Stroke;   Vascular Disease
Intervention:
34 Recruiting Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
Condition: Von Hippel-Lindau Disease
Intervention:
35 Recruiting Cause of Familial Testicular Cancer
Condition: Testicular Cancer
Intervention:
36 Recruiting Study of Mycobacterial Infections
Conditions: Atypical Mycobacterium Infections;   Cystic Fibrosis;   Job's Syndrome
Intervention:
37 Recruiting Study of Alkaptonuria
Condition: Alkaptonuria
Intervention:
38 Recruiting Genetic Studies of Chronic Active Epstein-Barr Disease
Condition: Epstein-Barr Virus Infections
Intervention:
39 Recruiting Study of Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention:
40 Recruiting Natural History of Familial Carcinoid Tumor
Condition: Carcinoid
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-54) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.